Clinical Trial Update: Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cemiplimab alone or in combination with fianlimab (and other experimental agents) for peri-operative stage III/IV cutaneous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Fianlimab (fianlimab)
• Libtayo (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN